Future research will therefore demonstrate how important the Wnt–β-catenin signalling pathway is for the self-renewal of cancer stem cells. The past two decades have seen a number of cases in ...

The trial will be a collaborative effort between the company, the Norwegian Cancer Society, and Cancer Research UK.

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with ...

The aberrant expression of partner of NOB1 homolog (PNO1) is known to promote oncogenesis in the colorectum and the esophagus, but its involvement in ovarian cancer and the mechanisms behind it are ...

By understanding how SOX9 governs Wnt/β-catenin signaling and EMT, we can identify potential new therapeutic strategies to treat this condition." The implications of these findings extend beyond ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...

Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...